| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Socioeconomic status (SES) is reflecting differences in
sociodemographic factors affecting cancer survivorship. Deprived, low
SES populations have a higher prevalence of multiple myeloma and worst
survival, a condition which widens over time.
Ethnicity/Racial Disparities in Myeloma Care
Novel Anti-Myeloma Agents and Disparities in Myeloma Care According to Race/Ethnicity
1. Data extracted from studies and included in this meta-analysis.
Single-center Experience on Myeloma Care in the Muslim Minority of Thrace, Greece
1. Myeloma care according to ethnicity/race in East Macedonia and
Thrace Greece. A) Disease
characteristics and therapy with new anti-myeloma agents or autologous
stem cell transplantation (ASCT) in Greeks and Greek Muslims. B) Progression Free
Survival after first line treatment according to ethnicity/race (PFS1).
Access to Medical Centers and Availability of Best Anti-Myeloma Care
Socioeconomic Status and Cancer Survivorship
Socioeconomic Status and Hematological Malignancies
Socioeconomic Status and Incidence of Multiple Myeloma
Socioeconomic Status and Myeloma Survival
Search Strategy and Statistical Analysis
2. Studies flow diagram and final selection of studies included in this
Combined from Eleven Studies Hazzard Ratio for Death in High SES and Low SES Myeloma Patients
Meta-analysis and combination of Hazzard Ratio (H.R.) extracted from 10
studies reporting H.R. (95 % CI) for overall survival (O.S.) according
to socioeconomic status (SES). B)
Synthesis of p values from 16 studies reporting H.R. (95 % CI) for O.S.
at 5 years according to SES segregating according to area of the globe
that data are coming from. In each table percentage of 5y O.S. from all
studies is reported and p values on the top denotes synthesis of p from
all studies in this part of the world.
Socioeconomic Status and Disparities in 5 Years Overall Survival of Myeloma Patients According to Geography
USA: Health System Disparities and the Impact of SES on Myeloma Survival
Australia: Health System Disparities and the Impact of SES on Myeloma Survival
New Zealand: Health System Disparities and the Impact of SES on Myeloma Survival
United Kingdom: Health System Disparities and the Impact of SES on Myeloma Survival
Greece: Health System Disparities and the Impact of SES on Myeloma Survival
Asia and Africa
Financial Toxicity of Myeloma Treatment